Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 26, 2026
Oramed Pharmaceuticals Inc. (ORMP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$202,000. As of Jun 30, 2026 it held $38.0 million in cash and investments and $733,000 in total debt.
Revenue
$0
-100.0% vs prior quarter
Net income
$78.16M
+488.2% vs year-ago quarter
Operating cash flow
$-200,000
+94.3% vs year-ago quarter
Free cash flow
$-202,000
+94.3% vs year-ago quarter
EPS
$1.84
+493.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
41.60M
+1.4% vs year-ago quarter
Net cash
$37.22M
Q2 FY2026
Operating margin
-121.4%
Q3 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORMP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1176309
- Former names
- Integrated Security Technologies, Inc. (until Apr 10, 2006); IGUANA VENTURES LTD (until Jun 10, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $2.0M | $0 |
| Operating income | -$2.8M | -$3.7M | -$5.7M | -$2.4M | -$2.5M |
| Net income | $78.2M | $38.3M | $10.0M | $48.4M | $13.3M |
| Diluted EPS | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 |
| Operating cash flow | -$200,000 | -$2.9M | -$466,000 | -$1.6M | -$3.5M |
| Free cash flow | -$202,000 | -$2.9M | -$468,000 | -$1.6M | -$3.5M |
| Total assets | $369.6M | $268.8M | $230.9M | $220.5M | $161.7M |
| Stockholders' equity | $317.5M | $238.3M | $199.7M | $202.3M | $153.6M |
| Cash and investments | $38.0M | $36.1M | $59.7M | $57.1M | $17.6M |
| Total debt | $733,000 | $761,000 | $825,000 | $860,000 | $912,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 17, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jun 30, 2026 | Jun 25, 2026 |
| 10-Q | Quarterly report | May 19, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Mar 31, 2026 | Mar 25, 2026 |
All 941 Oramed Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.